- Home
- FHTX vs MREO Comparison
FHTX vs MREO Comparison
Compare FHTX & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FHTX
- MREO
- Stock Information
- Founded
- FHTX 2015
- MREO 2015
- Country
- FHTX United States
- MREO United Kingdom
- Employees
- FHTX N/A
- MREO N/A
- Industry
- FHTX Medicinal Chemicals and Botanical Products
- MREO Biotechnology: Pharmaceutical Preparations
- Sector
- FHTX Health Care
- MREO Health Care
- Exchange
- FHTX Nasdaq
- MREO Nasdaq
- Market Cap
- FHTX 278.1M
- MREO 311.8M
- IPO Year
- FHTX 2020
- MREO N/A
- Fundamental
- Price
- FHTX $4.23
- MREO $1.92
- Analyst Decision
- FHTX Strong Buy
- MREO Strong Buy
- Analyst Count
- FHTX 5
- MREO 5
- Target Price
- FHTX $11.80
- MREO $7.40
- AVG Volume (30 Days)
- FHTX 270.7K
- MREO 1.7M
- Earning Date
- FHTX 10-31-2025
- MREO 11-12-2025
- Dividend Yield
- FHTX N/A
- MREO N/A
- EPS Growth
- FHTX N/A
- MREO N/A
- EPS
- FHTX N/A
- MREO N/A
- Revenue
- FHTX $24,173,000.00
- MREO $500,000.00
- Revenue This Year
- FHTX $42.43
- MREO N/A
- Revenue Next Year
- FHTX $14.77
- MREO $72.16
- P/E Ratio
- FHTX N/A
- MREO N/A
- Revenue Growth
- FHTX N/A
- MREO N/A
- 52 Week Low
- FHTX $2.95
- MREO $1.47
- 52 Week High
- FHTX $9.70
- MREO $4.40
- Technical
- Relative Strength Index (RSI)
- FHTX 45.28
- MREO 46.14
- Support Level
- FHTX $3.85
- MREO $1.98
- Resistance Level
- FHTX $4.69
- MREO $2.28
- Average True Range (ATR)
- FHTX 0.33
- MREO 0.13
- MACD
- FHTX 0.04
- MREO -0.02
- Stochastic Oscillator
- FHTX 55.77
- MREO 2.71
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).